Drug firms accused of pay-for-delay deal

By The Press Association2013-04-19T09:23:00

Source: Creative images

Drugs giant GlaxoSmithKline has been accused by the competition watchdog of paying firms to delay the launch of cheaper versions of its antidepressant treatment, in a move which denied the NHS “significant” cost savings.

You need to be a subscriber to read more

Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

All HSJ news by sector, topic & region
Breaking News announcements
App for mobile and offline reading
Comment and Daily Insights newsletters
Regional roundup newsletters
Unrestricted access to ‘Ask HSJ’ - AI assistant - AI assistant
10 expert briefings every fortnight (Premium only)

to HSJ

Already a subscriber? Sign into your account here